8-K: Scilex Holding Co. Secures Royalty Purchase Agreement and Gloperba License Agreement

Scilex Holding Company finalizes agreements for royalty rights and licensing to bolster financial position and global market reach.

Summary

• Scilex Holding Company entered into a Royalty Purchase Agreement on February 28, 2025, selling a 4% right to receive net sales worldwide for Gloperba and Elyxyb to institutional investors and Oramed Pharmaceuticals Inc.
• This agreement includes related, improved, successor, replacement, and/or varying dosage forms of the covered products.
• In return for the royalty rights, Scilex received a further deferral of the First Amortization Payment on Tranche B Notes until October 8, 2026.
• Scilex also entered into a Security Agreement, securing the obligations under the Royalty Purchase Agreement with collateral related to the Covered Products.
• A Subordination Agreement was established, giving the Royalty Purchase Agreement first priority liens on the Royalty Collateral.
• Amendment No. 1 to the ZTlido Royalty Purchase Agreement allows Scilex to assign its rights under certain conditions related to a potential asset purchase.
• Scilex granted RoyaltyVest Ltd. an exclusive worldwide license (excluding the United States) to develop, manufacture, and commercialize Gloperba products under a Gloperba License Agreement.
• Under the Gloperba License Agreement, each of the Licensee and the Company will receive 50% of the Net Revenue generated based on Licensees sale of the Gloperba Products.

Sentiment

Score: 7

Explanation: The document outlines strategic agreements that are likely to benefit Scilex in the long term, but there are also some potential risks and limitations associated with these deals.

Positives

• The Royalty Purchase Agreement provides Scilex with immediate capital and defers debt obligations.
• The Gloperba License Agreement allows Scilex to expand its global reach without direct investment outside the United States.
• The agreements include provisions for future product variations, ensuring long-term revenue potential.
• The Subordination Agreement prioritizes the Royalty Purchase Agreement, enhancing its security.

Negatives

• Selling a percentage of net sales reduces Scilex's potential future revenue from Gloperba and Elyxyb.
• The Gloperba License Agreement excludes the United States, potentially limiting Scilex's control over its product in a key market.
• The Royalty Purchase Agreement requires Scilex Pharma to pay each RPA Purchaser their Specified Percentage of the Covered Product Revenue Payments for each calendar quarter, commencing with the calendar quarter beginning January 1, 2025.

Risks

• The success of the Royalty Purchase Agreement depends on the continued sales performance of Gloperba and Elyxyb.
• The Gloperba License Agreement relies on RoyaltyVest Ltd.'s ability to successfully commercialize the product outside the United States.
• Changes in regulations or market conditions could impact the profitability of the licensed products.
• Failure to meet obligations under the Security Agreement could result in loss of collateral.

Future Outlook

The agreements position Scilex for continued growth and expansion in the global market, with a focus on maximizing the value of its key products.

Industry Context

These agreements reflect a trend in the pharmaceutical industry towards strategic partnerships and licensing deals to optimize product development and commercialization efforts.

Comparison to Industry Standards

• Royalty agreements in the pharmaceutical industry typically range from single to double digit percentages of net sales, depending on the stage of development, market potential, and exclusivity.
• Licensing agreements often involve upfront payments, milestone payments, and royalties on future sales, with terms varying based on the specific assets and market conditions.
• Comparable companies like Sorrento Therapeutics and Pain Therapeutics have engaged in similar royalty and licensing deals to fund operations and expand their product portfolios.
• The 4% royalty rate for Gloperba and Elyxyb is relatively low, suggesting that Scilex may have prioritized immediate capital over long-term revenue potential.

Stakeholder Impact

• Shareholders may benefit from the increased financial stability and global market access.
• Employees may see new opportunities for growth and development.
• Customers may have access to improved products and services.
• Suppliers may benefit from increased demand for their products.

Next Steps

• Licensee to obtain and maintain regulatory approval for Gloperba outside of the United States.
• Facilitate introduction between Licensee and Companys contract manufacturer of the Gloperba Product.
• Licensee to obtain and maintain regulatory approval for the Gloperba Product outside of the United States in accordance with its own business judgment and in its sole and absolute discretion.

Key Dates